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Objective: To evaluate the efﬁcacy and safety of chondroitin sulfate and/or glucosamine hydrochloride in
alleviating symptoms and improving the dysfunction of Kashin-Beck disease (KBD) patients.
Methods: We undertook a cluster-randomized, placebo-controlled trial in 251 patients with KBD.
Participants were randomly allocated to comparing (1) chondroitin sulfate, (2) glucosamine hydro-
chloride, (3) a combination of chondroitin sulfate and glucosamine hydrochloride, or (4) placebo, for 6
months duration. The primary outcome measures of interest were 20% and 50% reductions in pain from
baseline, measured by pain subscale in the Western Ontario and McMaster Universities Osteoarthritis
(WOMAC) Index. Secondary outcome measures included parameters in the WOMAC Index such as pain,
stiffness, and physical function, as well as patients’ quality of life by the 12-item Short-Form General
Health Survey. The trial registration number is ChiCTR-TRC-11001480 (http://www.chictr.org/).
Results: A combination therapy of chondroitin sulfate and glucosamine hydrochloride was effective in
reducing WOMAC pain by 20% (differences of 23.4%, P¼ 0.006) and 50% (differences of 15.7%, P¼ 0.016),
WOMAC pain (P¼ 0.032), WOMAC stiffness (P¼ 0.043), and WOMAC total score (P¼ 0.035). Chondroitin
sulfate used alone was also found to be effective in reducing WOMAC total score and stiffness score
(P¼ 0.038 and P¼ 0.023, respectively). No signiﬁcant positive effects in improving WOMAC Index scores
were observed with glucosamine hydrochloride alone.
Conclusion: The ﬁndings of this study indicate that a combination of chondroitin sulfate and glucosamine
hydrochloride was more effective than placebo in treating KBD.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Kashin-Beck disease (KBD) is a degenerative osteoarticular
disease affecting the bones and joints1. The core pathological
feature of KBD is degradation of cartilages, which is similar to that
in osteoarthritis (OA)2. Eventual joint destruction leads to recurrent
and mostly bilateral joint pain, restriction of physical movement
and joint enlargement3. The most frequently affected sites are the
distal limb joints (e.g., ankles, knees, wrists and elbows)4. Theworst
forms of the disease tend to start in childhood and may result in
dwarﬁsm5. KBD is endemic to certain geographical areas, from
South-Eastern Siberia to North Korea, North-East to South-West of
China. About three million people are affected by KBD in China,Dong Birong, Department of
, Guoxuexiang 37, Chengdu,
.
g).
s Research Society International. PRussia and North Korea6. There are various hypotheses regarding
the etiology of KBD but the exact causes are unknown. It is likely
that KBD has a multifactorial origin7.
Treatment of KBD is mainly for palliative care, and selenium
supplementation has been given in some highly endemic areas for
a long time. The efﬁcacy of selenium supplementation for
prevention and treatment of KBD, however, is uncertain8e11. There
are other treatment options such as surgical corrections, physical
treatment, and non-steroidal anti-inﬂammatory drugs. Regrettably
most are not proven to be effective. Attention has thus been focused
on applying treatment for OA in KBD as both conditions share
a central pathological feature.
Chondroitin sulfate and glucosamine have been recognized as
symptomatic, slow-acting remedies for OA for decades. Numerous
studies have shown that glucosamine and chondroitin sulfate could
relieve pain and delay long-term progression of knee OA in terms of
joint structure changes and symptoms12e15. Furthermore, ﬁndings
from a randomized controlled trial (RCT) showed that chondroitinublished by Elsevier Ltd. All rights reserved.
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space narrowing when compared to placebo in adult patients with
KBD16. All the above suggest that chondroitin sulfate and glucos-
amine might play a protective role in preserving articular cartilage
and thus could be potential therapeutic agents in patients with
KBD. However, the aforementioned RCT did notmeasure pain relief,
physical function, or quality of life improvement. Therefore, the
complete beneﬁts of chondroitin sulfate and/or glucosamine are yet
to be established. With this aim in mind, we undertook a cluster-
randomized, placebo-controlled trial to evaluate the efﬁcacy and
safety of chondroitin sulfate and/or glucosamine hydrochloride in
alleviating symptoms and improving the dysfunction of KBD
patients during a 6-month treatment course.
Methods
Setting and participants
Our cluster-randomized, placebo-controlled trial was conducted
in the Nanmuda village of Rangtang County, Sichuan, China, which
is one of the endemic areas affected by KBD. Nanmuda village is
a semi-farming and semi-husbandry tribe, in which all residents
are Tibetan nationality. According to the epidemiological study, the
detection rate of KBD is 39.1% in Rangtang County17. The recent
2008 survey by the Chinese Center for Disease Control and
Prevention found that a total of 3641 residents lived in the
Nanmuda village (1826men and 1815women), of whom 1079were
KBD patients. We recruited patients with KBD who were available
to and capable of giving informed consent, and who planned to live
in the trial areas for at least 6 months. There was no age limit.
The clinical diagnosis and grading of KBD as well as differential
diagnosis with other bone disease (e.g., OA, osteoﬂuorosis and
rheumatoid arthritis) were made by orthopedic surgeons and
physicians of the Rheumatology Department of West China
Hospital, Sichuan University on the basis of clinical and radiological
criteria (GB 16003-1995)18. Patients were excluded on the
following criteria: (1) they had taken any medications for KBD
during 3 months before enrollment; (2) they had a history of, or
evidence of, speciﬁed confounding disorders (e.g., septic arthritis,
neoplasias, bone metabolic diseases, or OA); (3) history of clinically
signiﬁcant trauma or surgery to the index joint; (4) co-existing
diseases that could preclude successful completion of the trial;
(5) and pregnancy. The trial protocol was approved by the Insti-
tutional Review Boards at West China Hospital and was conducted
according to Good Clinical Practice guidelines and the Helsinki
Declaration II. Full informed consent (by signature or thumbprint)
was obtained from all trial participants. The trial registration
number is ChiCTR-TRC-11001480 (http://www.chictr.org/).
Procedures
For the baseline observational period, the results of routine
laboratory tests were collected, and clinical symptoms and physical
examination assessments were conducted. Eligible patients, in
clusters, were randomly assigned to one of four orally administered
treatments: (1) 600 mg of chondroitin sulfate twice daily,
(2) 480 mg glucosamine hydrochloride three times daily,
(3) a combination of glucosamine plus chondroitin sulfate as above,
or (4) placebo (consisted of starch only), for a period of 6 months.
Chondroitin sulfate was manufactured by Green Pharmaceutical
Factory, Chongqing, China. It contained 100 mg of sodium chon-
droitin sulfate A (chondroitin-4-sulfate) per tablet, which was from
extracts of cartilaginous pig tissues (trachea, ear and nose). This
product has been approved as a supplement for OA at a dosage
regime of 1200 mg per day in China. Glucosamine used in this studywas manufactured by Xin Si Dun Pharmaceutical Factory (Sichuan
Province, China). It contained 240 mg of D-glucosamine hydro-
chloride per tablet. It is approved as a supplement for OA at
a dosage of 1480 mg per day in China.
Chondroitin sulfate and glucosamine are both slow-acting
remedies and thus are unable to relieve pain during the ﬁrst
2 weeks of administration. In order to improve compliance,
participants in each group were allowed to take an additional
200 mg of celecoxib (Celebrex, Pﬁzer) daily during the ﬁrst 2 weeks
after randomization for pain relief. Participants in four groupsmust
have equal access to celecoxib to avoid interference to outcomes.
Other analgesics, including narcotics and paracetamol, were pro-
hibited. Home visits were carried out every 2weeks. Village doctors
gathered data on dosage that patients had missed, number of
unused sachets and any occurrence of adverse events from the time
of randomization to the end of the 6-month treatment course.
Participants were evaluated 6 months after randomization.
Randomization and allocation concealment
The patients were divided into clusters of family. The random-
ization list was generated by a computer in blocks of four, and every
family received their randomization number in chronological order.
The principal investigator was provided with single-sealed, opaque
envelopes, which contained the randomization codes for every
family cluster. Trial personnel had no access to the randomization
list or any information that would allow them to deduce or
manipulate the allocation sequence. Chondroitin sulfate, glucos-
amine, and placebo were different in numbers of tablets and
appearance and we did not use dummy intervention. However,
their identities were masked by naming them as “A”, “B”, “C” and
“D”. Therefore, although the participants and trial personnel
(including those distributing medicine and collecting, processing,
and analyzing data) were aware that the medications were
different they were unable to identify the exact type of
medications.
Outcome measures
The primary outcome measure was a response to treatment,
deﬁned as a 20% and 50% decrease in the summed score for the
Western Ontario and McMaster Universities Osteoarthritis
(WOMAC) pain subscale from baseline to sixth month.
The secondary outcome measures included the mean change in
WOMAC total scores and subscale scores (including pain, stiffness,
and physical function) after 6 months of treatment. The mean
change in quality of life as measured by the 12-item Short-Form
General Health Survey (SF-12) was also evaluated.
The WOMAC Index is a validated, disease-speciﬁc questionnaire
addressing severity of joint pain (ﬁve questions), stiffness (two
questions), and limitation of physical function (seventeen ques-
tions). The worst possible total score is 9619. SF-12, reﬂecting the
health-related quality of life, evaluates physical function (six
questions) and mental function (six questions), with a score range
from 6 to 5620. To prevent methodological errors and assure
methodological reliability, the administrator was trained by the
investigator by: (1) reviewing the WOMAC and SF-12 procedures
and grading system outlined in a short booklet and video;
(2) observing an experienced rheumatologists in the conduct of
WOMAC and SF-12 procedures.
Adverse events
Safety variables included adverse events, serious adverse events
and laboratory evaluations. Adverse events were graded according
J. Yue et al. / Osteoarthritis and Cartilage 20 (2012) 622e629624to qualitative assessment of the extent or intensity of the adverse
events by the investigator, or reported by the patients. Serious
adverse events were deﬁned as any fatal or immediate life-
threatening clinical experience or disabling event. Laboratory
evaluations included complete blood counts, measurement of
serum alanine transaminase (ALT), glutamic-oxalacetic trans-
aminase (AST), alkaline phosphatase (ALP), urea nitrogen (BUN),
creatinine (CREA), uric acid (UA), and glucose (GLU).Statistical analysis
We calculated sample size on the basis of outcomes of Glucos-
amine/Chondroitin Arthritis Intervention Trial (GAIT)21. Incidences
of reducing pain by 20% were 64.1%, 65.4% and 66.6% in the
glucosamine group, the chondroitin sulfate group, and the
combined-treatment group, respectively. Assuming a rate of
response of 35% in the placebo group, a Type I error of 5%, and
a Type II error of 20%, a sample size of 196 patients (49 participants
per group) was calculated, and this was increased to at least 248
patients (62 participants per group) to take into account an
expected dropout rate of 20%. The sample size was calculated using





p  2 sin1 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃpmin
p 2
The chi-square test was used to compare categorical data (e.g.,
primary outcomes). Comparisons of each of the three treatment
groups with the placebo group were made with a Type 1 error at
0.017 for each comparison (adjusted for three primary comparisonsFig. 1. Trialagainst placebo). One-way Analysis of Variance (ANOVA) followed
by post-hoc test (Dunnett’s test) was used to evaluate quantitative
data (e.g., secondary outcomes). Multiple comparisons of each of
the three treatment groupswith the placebo groupweremadewith
a Type 1 error at 0.05. Analyses of the categorical data (e.g., primary
outcomes) were conducted according to the intention-to-treat
principle. A per-protocol analysis was performed in quantitative
data (e.g., secondary outcomes). All statistical tests were two sided.
We used Statistical Product and Service Solutions (SPSS) 13.0
software for all statistical analyses.
Results
Baseline characteristics
Recruitment began on nineteenth June, 2009 inNanmuda villages
of Rangtang county, Sichuan, China, and was completed on eighth
July, 2010. A total of 764 participants were screened, of which 251
(from 38 families) were randomized. Participants were divided into
four groups by the cluster randomization method to receive either
chondroitin sulfate (n¼ 64), glucosamine hydrochloride (n¼ 62),
a combination of chondroitin sulfate and glucosamine (n¼ 63), or
placebo (n¼ 62) (Fig. 1). The most common reasons for exclusion
were not meeting full inclusion criteria (n¼ 312) and not agreeing to
blood samples being taken (n¼ 186). Majority of participants were
female (54.6%). The age of participants ranged from 13 to 86 years
with amean age of 51.73 years. Themean bodymass index (BMI)was
23.82 and themean course of KBDwas 25 years. The four groups had
nosigniﬁcantdifferencesatbaseline (Table I), and thewithdrawal rate
of 43/251 (17.1%) did not differ signiﬁcantly amongst groups (Fig. 1).proﬁle.
Table I
Baseline characteristics
Data Chondroitin sulfate (n¼ 64) Glucosamine hydrochloride (n¼ 62) Combination (n¼ 63) Placebo (n¼ 62)
Age-year 51.33 12.48 51.45 13.91 51.29 14.76 52.87 15.41
Male-no. (%) 31 (48.4) 27 (43.5) 27 (42.9) 29 (46.8)
Height-cm 158.59 12.36 160.08 9.82 158.44 11.61 159.66 12.41
Weight-kg 62.31 14.36 59.11 12.63 59.24 13.68 61.66 15.18
BMI-kg/m2 24.71 4.66 23.01 4.03 23.51 4.66 24.05 4.74
SBP-mmHg 127.91 22.03 126.60 18.31 128.41 20.50 129.01 16.89
DBP-mmHg 79.30 13.68 79.73 11.06 80.14 13.89 80.71 13.06
Course-year 24.78 17.75 25.29 17.86 24.35 21.10 25.61 16.25
Grade-n(%)
I 42 (65.6%) 41 (66.1%) 40 (63.5%) 40 (64.5%)
II 12 (18.8%) 13 (21.0%) 11 (24.5%) 12 (19.4%)
III 10 (15.6%) 8 (12.9%) 12 (19.0%) 10 (16.1%)
WOMAC score
Pain 10.38 4.12 9.79 4.44 10.51 4.48 10.06 4.94
Stiffness 3.23 2.14 2.95 2.18 2.27 2.14 2.62 2.01
Function 34.91 12.84 32.20 15.59 35.90 17.36 33.37 14.64
Total 48.52 18.09 44.94 21.37 49.68 23.41 46.06 20.25
SF-12 34.09 3.36 35.52 3.79 33.53 3.30 33.60 3.21
Complete blood count
WBC-109/L 6.58 2.07 6.65 2.00 6.41 1.72 6.78 1.94
RBC-1012/L 5.17 0.67 5.07 0.85 5.00 0.85 5.26 0.62
HGB-g/L 149.80 22.50 145.50 30.93 149.19 28.85 146.56 26.31
PLT-109/L 245.30 75.31 245.24 80.67 246.00 60.03 253.56 63.69
Blood biochemical item
ALT-IU/L 33.31 27.23 41.18 37.97 40.06 35.06 31.27 19.86
AST-IU/L 44.20 21.82 42.63 21.40 45.81 18.53 39.11 21.49
ALP-IU/L 90.02 32.81 91.19 49.51 99.00 42.71 94.73 76.99
BUN-mmol/L 5.89 2.16 5.98 2.09 5.84 1.94 5.63 2.33
CREA-umol/L 74.44 24.05 76.56 21.15 71.06 20.29 72.05 20.16
UA-umol/L 351.44 89.24 378.48 89.15 354.85 95.07 363.90 90.50
GLU-mmol/L 4.06 0.70 4.11 1.08 3.91 1.18 4.14 1.30
Pluseminus values are means standard deviation. SBP: systolic blood pressure, DBP: diastolic blood pressure, WBC: white blood cell, RBC: red blood cell, HGB: hemoglobin,
PLT: platelet.
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Results of primaryoutcomemeasures are given inTable II. The rate
of response (20%decrease inWOMACpain) in the combination group
was signiﬁcantly higher than that in the placebo control (differences
of 23.4%,P¼ 0.006). Although the rates of response in the chondroitin
sulfate group and glucosamine group were higher than placebo
(differences of 18%, and 8.1%, respectively), there was no statistical
signiﬁcance. The response rates of 50% decrease in WOMAC pain
showed a similar pattern, with insigniﬁcant differences between
placebo group and chondroitin sulfate group (differences of 12.2%,
P¼ 0.049) as well as glucosamine group (differences of 11.3%,
P¼ 0.068). The combination groups (differences of 15.7%, P¼ 0.016)
being statistically superior to the placebo group.
For secondary outcome measures (Table III), the combined











20% Decrease in WOMAC pain score
n (%) 27 (42.2) 20 (32.3) 30 (47.6) 15 (24.2)
P value (c2) 0.032 (4.588) 0.318 (0.995) 0.006 (7.442)* e
50% Decrease in WOMAC pain score
n (%) 13 (20.3) 12 (19.4) 15 (23.8) 5 (8.1)
P value (c2) 0.049 (3.858) 0.068 (3.340) 0.016 (5.764)* e
*: P< 0.017. All P values are for the comparison with the placebo group at end of
follow-up.total score (P¼ 0.035), WOMAC pain (P¼ 0.032) and WOMAC
stiffness score (P¼ 0.043). WOMAC total score and stiffness score
were also signiﬁcantly improvedwith chondroitin sulfate thanwith
placebo (P¼ 0.038 and P¼ 0.023, respectively). Effects by glucos-
amine as compared to placebo were insigniﬁcant. For WOMAC
function score and the SF-12, there were no signiﬁcant differences
between the placebo group and the chondroitin sulfate, glucos-
amine, or combination groups.
Adverse events
Adverse events reported were generally mild and evenly
distributed amongst groups. A total of 23 adverse events were
reported in 18 patients. No serious adverse events were reported.
The number of patients who withdrew because of adverse events
was similar among the groups (Fig. 1). The incidence of adverse
events was similar across the four groups (Table IV). In general,
notable abnormal laboratory test results did not follow any clini-
cally relevant pattern in any treatment group.
Discussion
Due to an increased prevalence of KBD and a lack of effective
therapies, many studies on treatment of KBD were carried out in
recent years. One meta-analysis demonstrated the beneﬁts of sele-
nium supplementation for the primary prevention of KBD in chil-
dren22. Chinese and Russian orthopedists have also reported
successful treatment of joint defects by surgical means23,24. Some
authors have employed physical therapy in the treatment of KBD
since it can relieve pain, improve mobility and thus improve the
Table III
Mean change (95% CI) from baseline in the secondary outcomes
Reduction from baseline Chondroitin sulfate (n¼ 54) Glucosamine hydrochloride (n¼ 51) Combination (n¼ 52) Placebo (n¼ 51)
WOMAC total score
Change 6.59 (1.48, 14.67) 3.59 (12.20, 5.02) 6.90 (2.61, 16.42) 7.82 (14.54, 1.11)
MD 14.42 (0.65, 28.18) 4.24 (9.73, 18.20) 14.73 (0.83, 28.62) e
P value 0.038* 0.813 0.035* e
WOMAC pain score
Change 1.74 (0.13, 3.35) 0.41 (1.25, 2.07) 2.02 (0.24, 3.80) 1.04 (2.80, 0.73)
MD 2.78 (0.05, 5.61) 1.45 (1.42, 4.32) 3.06 (0.20, 5.91) e
P value 0.055 0.488 0.032* e
WOMAC stiffness score
Change 0.72 (0.10, 1.54) 0.25 (1.05, 0.54) 0.60 (0.25, 1.44) 0.82 (1.66, 0.02)
MD 1.55 (0.18, 2.92) 0.57 (0.82, 1.96) 1.42 (0.04, 2.80) e
P value 0.023* 0.646 0.043* e
WOMAC function score
Change 4.13 (1.86, 10.12) 3.75 (10.37, 2.87) 4.29 (2.92, 11.50) 5.96 (10.74, 1.18)
MD 10.09 (0.23, 20.41) 2.22 (8.25, 12.68) 10.25 (0.17, 20.66) e
P value 0.057 0.924 0.055 e
SF-12
Change 0.22 (1.71, 1.26) 1.20 (0.06, 2.45) 0.02 (1.65, 1.61) 0.00 (1.57, 1.57)
MD 0.22 (2.70, 2.26) 1.20 (1.32, 3.71) 0.02 (2.52, 2.48) e
P value 0.993 0.536 1.000 e
*: P< 0.05. All P values and 95% conﬁdence intervals of the differences vs placebo were derived by Dunnett’s two-tailed test with adjustment for multiple comparisons. CI:
conﬁdence interval. MD: Mean difference from placebo..
J. Yue et al. / Osteoarthritis and Cartilage 20 (2012) 622e629626socio-economic status of patients25,26. A 6-week RCT found that
celecoxib and meloxicam provided effective relief from the symp-
toms of KBD (WOMAC pain and stiffness)27. Another study found
that intra-articular injections of sodium hyaluronate can improve
the function in knee of patients and relieve their symptoms of
KBD28. Up to now, main issues in caring for patients with KBD are
effective pain relief as well as improving their functional disability.
Our studydemonstrated that combinatorychondroitin sulfate and
glucosamine hydrochloride therapy was more effective in terms of
treatment response (20% and 50% decrease in WOMAC pain, respec-
tively). Both the combination or chondroitin sulfate alone were
effective in relieving the joint stiffness, but they failed to improve
overall physical function and quality of life measured by SF-12.
No signiﬁcant beneﬁts were identiﬁed with the use of glucosamine
hydrochloride. Adverse events reported were similar amongst treat-
ment and placebo groups. Contrary to available research ﬁndings, we
did not identify an increase in blood GLU with the administration of
glucosamine. We noted a low success rate in improving WOMAC
scores aswell asworseningof symptomswith the use of placebo. This
may be explained by the fact that our included participants were
forbidden to take any additional analgesics besides 2 weeks of cele-
coxib. Since most of our participants had taken corticosteroids or












Dyspepsia 1 2 1 1
Abdominal pain 2 1 0 1
Diarrhea 0 1 1 0
Constipation 1 0 0 1
Nausea 0 1 2 1
Skin rash 1 0 0 1
Cough 0 0 1 0
Headache 0 1 1 1
Dizziness 0 0 0 0
Total number
of incidence
5 6 6 6taking part in our study, conditions could have been aggravatedwith
the lack of co-interventions in the placebo group.
Chondroitin sulfate and glucosamine are used widely in OA and
their efﬁcacy and safety proﬁles in the treatment of OA are well
established. Due to the similar pathological features of KBD and OA,
we thereby investigated the applicability of chondroitin sulfate and
glucosamine in KBD. Our study showed that combinatory chon-
droitin sulfate and glucosamine therapy were effective in relieving
joint pain and improving joint stiffness. Our results are in agreement
with some previous studies12e15,29,30. Particularly, the famous GAIT
study showed that a combination of chondroitin sulfate and
glucosamine may be effective in patients with moderate to severe
symptoms of OA21. In addition, one study used chondroitin sulfate
and glucosamine to treat adult patients with KBD for 8 months. It
found that treatment with chondroitin sulfate and glucosamine in
KBD was associated with an absence of change in femorotibial joint
space width16. Chondroitin sulfate is a glycosaminoglycan with
a polymerized disaccharide base linked to a sulfate group and is
found in the proteoglycans of articular cartilage31. Glucosamine is an
aminosaccharide which acts as a preferred substrate for the
biosynthesis of glycosaminoglycan chains and, subsequently, for the
production of aggrecan and other proteoglycans in cartilage32. In
addition, sulfate salts have been suggested to be an important
component in glucosamine’s mechanism of action by elevating
levels of glucosamine metabolites33,34. This may explain the signif-
icant results in our study when glucosamine hydrochloride was co-
administered with chondroitin sulfate. Chondroitin sulfate and
glucosamine might play a protective role in preserving articular
cartilage and provide evidence for therapeutic drugs in adult
patients with KBD.
Interestingly, our study found that glucosamine hydrochloride
was ineffective in the treatment of KBD. This result was inconsis-
tent with other published datawhich conﬁrmed the positive effects
of glucosamine for OA12e15,35e37. However, there is already some
conﬂicting evidence on the effectiveness of glucosamine in
OA38e43. Using an anterior cruciate ligament deﬁcient model of
acute OA in the rabbit and daily glucosamine hydrochloride dosing
for 8 weeks, starting 3 weeks after surgery, effects on most
outcomes were insigniﬁcant44. One meta-analysis evaluated the
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radiological progression of OA of the hip or knee. On a 10-cm visual
analog scale, the overall difference in pain intensity, glucosamine
hydrochloride did not show any signiﬁcant effect when compared
to placebo. For glucosamine sulfate, there is a marginally signiﬁcant
difference compared with placebo. However, after excluded low
quality studies (e.g., non-blinded, not taken intention-to-treat
analysis, no concealment of allocations), glucosamine sulfate was
also had no signiﬁcant difference42. Another Cochrane review of
glucosamine for OA found that glucosamine was ineffective for
alleviating pain45.
How do we explain the difference between the positive in vitro
effects against the negative effects of glucosamine shown in some
published clinical trials? A possible explanation could be the
pharmacodynamics proﬁle of glucosamine. In vitro studies
demonstrated that plasma concentrations of 50e5000 mmol/L are
required for glucosamine to exert therapeutic effect in OA46.
However, as reported by Biggee et al. in a study of 18 participants
with OA who were given 1500 mg of glucosamine sulfate after an
overnight fast. Their peak serum glucosamine concentrations were
detected at 90e180 min, with a range of 1.9e11.5 mmol/L47.
This phenomenon raises questions about the current biological
rationale of glucosamine usage that are based on in vitro effects
only observed at high concentrations.
Our study has a number of limitations. Firstly, the duration of
follow-up was relatively short. Some outcomes such as WOMAC
physical function and quality of life measured by SF-12 could not be
effectively assessed in such a short duration. Secondly, the evaluation
was only performed at 6-month with no assessment between
baseline to 6months. Thiswas due to tough circumstances inTibetan
Plateau with restricted access, high altitude of >4000 m and limited
local medical equipment. Furthermore, participants lived in scat-
tered, remote areas and were difﬁcult to re-group them for assess-
ment. Thirdly, blinding was not performed in our study. However,
scattered living conditions limited communication and contamina-
tion. The patients would hardly know what they were being allo-
cated and how it could be different from another family member.
Finally, the outcomemeasures includedwereWOMAC scores and SF-
12, instead of the impersonal outcomes such as reduction of joint
space width. This was due to practical problems. The outcome
measure of joint space width is based on the effectiveness of X-ray
treatment. Rangtang Country is a remotemountainous area and only
one X-ray machine is available in the main country hospital. Partic-
ipants must therefore walk 10e30 km in treacherous conditions to
reach the country hospital. Therefore it was difﬁcult to provide X-ray
follow-up examination for every participant.
In conclusion, the ﬁndings of our study indicate that a combi-
nation of chondroitin sulfate and glucosamine hydrochloride is
more effective than placebo in treating KBD (for joint pain and
stiffness). Chondroitin sulfate alone was also effective in relieving
joint stiffness. Chondroitin sulfate and glucosamine hydrochloride
were found to be relatively safe in our 6-month treatment period.
Continuing research is needed to establish the long-term effects
and safety of chondroitin sulfate and glucosamine hydrochloride,
and the efﬁcacy of X-ray examination for KBD patients. In fact, we
have planned to undertake a following study to observe the effect
of chondroitin sulfate and glucosamine on KBD for 3 years with
a follow-up visit every 3 months.
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